Bull Harbor Capital LLC Purchases New Holdings in Incyte Corporation $INCY

Bull Harbor Capital LLC acquired a new stake in shares of Incyte Corporation (NASDAQ:INCY) in the first quarter, HoldingsChannel reports. The fund acquired 14,471 shares of the biopharmaceutical company’s stock, valued at approximately $1,362,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Geode Capital Management LLC boosted its stake in shares of Incyte by 11.3% during the 4th quarter. Geode Capital Management LLC now owns 4,993,012 shares of the biopharmaceutical company’s stock valued at $491,500,000 after buying an additional 506,842 shares during the last quarter. Invesco Ltd. grew its position in shares of Incyte by 13.2% during the fourth quarter. Invesco Ltd. now owns 3,473,781 shares of the biopharmaceutical company’s stock worth $343,105,000 after buying an additional 405,611 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its position in shares of Incyte by 13.7% during the third quarter. Arrowstreet Capital Limited Partnership now owns 3,103,946 shares of the biopharmaceutical company’s stock worth $263,246,000 after buying an additional 373,298 shares in the last quarter. Morgan Stanley increased its stake in shares of Incyte by 0.9% in the fourth quarter. Morgan Stanley now owns 2,663,823 shares of the biopharmaceutical company’s stock worth $263,106,000 after buying an additional 23,087 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. increased its stake in shares of Incyte by 7.0% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 2,480,793 shares of the biopharmaceutical company’s stock worth $245,028,000 after buying an additional 161,405 shares during the last quarter. 96.97% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

INCY has been the topic of several recent analyst reports. Citigroup reaffirmed a “market perform” rating on shares of Incyte in a report on Wednesday, July 15th. TD Cowen reissued a “hold” rating on shares of Incyte in a report on Tuesday, June 9th. Oppenheimer reissued a “market perform” rating and issued a $120.00 target price on shares of Incyte in a research report on Tuesday. BMO Capital Markets upped their target price on shares of Incyte from $112.00 to $130.00 and gave the company a “market perform” rating in a research note on Wednesday. Finally, Sanford C. Bernstein initiated coverage on shares of Incyte in a research report on Thursday, May 21st. They set a “market perform” rating and a $99.00 price target on the stock. Eight equities research analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $117.74.

Incyte News Roundup

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Strong Q2 results: Incyte reported $1.67 billion in revenue, up 37.7% year over year, and adjusted earnings of $3.09 per share versus the $2.20 consensus estimate. Growth was led by Jakafi, Opzelura and the company’s hematology and oncology portfolio. INCY Q2 Earnings and Revenues Beat
• Positive Sentiment: Higher full-year outlook: Management raised 2026 total net-sales guidance to $5.13 billion-$5.26 billion from $4.77 billion-$4.94 billion. Opzelura guidance was increased to $1.05 billion-$1.10 billion, helped by a CMS settlement expected to contribute approximately $300 million-$310 million. Incyte Raises 2026 Sales Forecast
• Positive Sentiment: Analyst target increases: HC Wainwright raised its target to $150 from $140 and kept a Buy rating, while BMO lifted its target to $130 from $112. Analysts cited stronger commercial momentum, pipeline progress and a broader product base. Analysts Raise Incyte Forecasts
• Neutral Sentiment: Incyte expects 10 clinical data readouts, including four registrational trials, in the second half of 2026. These could create catalysts but also increase clinical execution risk.
• Negative Sentiment: UBS reiterated a Hold rating with an unchanged $113 target, arguing that the recent rally limits near-term upside. A separate analysis also downgraded the stock from Buy to Hold after its substantial advance. UBS Reiterates Hold on Incyte
• Negative Sentiment: The Opzelura benefit includes a $246 million one-time, non-cash accounting benefit from the CMS settlement, making some of the guidance increase less indicative of recurring operating growth. Several company insiders have also sold shares without reported purchases in the past six months.

Incyte Stock Performance

Incyte stock opened at $127.10 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.53 and a quick ratio of 3.60. Incyte Corporation has a 12 month low of $73.81 and a 12 month high of $132.60. The company has a fifty day moving average price of $108.59 and a two-hundred day moving average price of $102.00. The company has a market cap of $25.39 billion, a PE ratio of 16.19, a P/E/G ratio of 1.13 and a beta of 0.76.

Incyte (NASDAQ:INCY) last issued its earnings results on Tuesday, July 28th. The biopharmaceutical company reported $3.09 earnings per share for the quarter, topping analysts’ consensus estimates of $2.15 by $0.94. Incyte had a net margin of 27.71% and a return on equity of 29.93%. The company had revenue of $1.67 billion for the quarter, compared to analysts’ expectations of $1.50 billion. During the same period in the prior year, the company earned $1.57 earnings per share. The firm’s revenue was up 37.7% compared to the same quarter last year. Research analysts expect that Incyte Corporation will post 6.9 earnings per share for the current year.

Incyte Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.